Role of smpB in E. coli Antibiotic Sensitivity via CRISPR Interference
DOI:
https://doi.org/10.54097/d85rvk70Keywords:
CRISPRi, smpB, Escherichia Coli, Antibiotic Sensitivity, Spectinomycin, ChloramphenicolAbstract
Multidrug-resistant bacteria are on the increase, which underscores the necessity of effective treatment. E. coli smpB gene encodes a system that helps in saving stalled ribosomes during translation stress, which could help the bacteria to survive in antibiotic stress by keeping the protein synthesis process going. The purpose of this research project was to determine whether CRISPR interference (CRISPRi) of smpB can make E. coli susceptible to antibiotics and modify cell growth under the experimental conditions. CRISPRi plasmids carrying two guide RNAs that target the smpB gene were cloned and transformed into E. coli strains LC-E75 and WM6026. Colony PCR and gel electrophoresis were used to check insertion and gave bands at the expected position of 416 bp. The sensitivity to antibiotics was then determined with disks of spectinomycin, chloramphenicol and a combination of both at low and medium concentration. The measurements of zones of inhibition were performed on 42 plates with various strains of E. coli and gRNA models. The results indicated that smpB-targeting CRISPRi was linked with higher antibiotic sensitivity in WM6026 strain compared to minimal impact in LC-E75 strain. A cell viability experiment in WM6026 indicated that CRISPRi activation did not have a significant impact on the growth without antibiotics. These results indicate that smpB can be involved in the antibiotic stress response and promote the continued research of the CRISPRi-based studies of bacterial genes.
Downloads
References
[1] L. Poirel, J.-Y. Madec, A. Lupo, A.-K. Schink, N. Kieffer, P. Nordmann, and S. Schwarz, “Antimicrobial Resistance in Escherichia coli,” Microbiology Spectrum, 2018, Vol. 6 (4). doi: 10.1128/microbiolspec.ARBA-0026-2017.
[2] M. M. Walker, J. A. Roberts, B. A. Rogers, P. N. A. Harris, and F. B. Sime, “Current and Emerging Treatment Options for Multidrug-Resistant Escherichia coli Urosepsis: A Review,” Antibiotics, 2022, Vol. 11 (12), 1821. doi: 10.3390/ antibiotics 11121821.
[3] J. N. V. Martinson and S. T. Walk, “Escherichia coli Residency in the Gut of Healthy Human Adults,” EcoSal Plus, 2020, Vol. 9 (1). doi: 10.1128/ecosalplus.ESP-0003-2020.
[4] K. Hanawa-Suetsugu, M. Takagi, H. Inokuchi, H. Himeno, and A. Muto, “SmpB Functions in Various Steps of Trans-Translation,” Nucleic Acids Research, 2002, Vol. 30 (7), pp. 1620-1629. doi: 10.1093/nar/30.7.1620.
[5] A. W. Karzai, M. M. Susskind, and R. T. Sauer, “SmpB, a Unique RNA-Binding Protein Essential for the Peptide-Tagging Activity of SsrA (tmRNA),” The EMBO Journal, 1999, Vol. 18 (13), pp. 3793-3799. doi: 10.1093/emboj/ 18. 13. 3793.
[6] M. Aswal, N. Singh, N. Singhal, and M. Kumar, “An Integrated Proteo-Transcriptomics Approach Reveals Novel Drug Targets Against Multidrug-Resistant Escherichia coli,” Frontiers in Microbiology, 2025, Vol. 16, 1531739. doi: 10.3389/ fmicb. 2025. 1531739.
[7] J. Li, L. Ji, W. Shi, J. Xie, and Y. Zhang, “Trans-Translation Mediates Tolerance to Multiple Antibiotics and Stresses in Escherichia coli,” Journal of Antimicrobial Chemotherapy, 2013, Vol. 68 (11), pp. 2477-2481. doi: 10.1093/jac/dkt231.
[8] A. B. Banta, R. D. Ward, J. S. Tran, E. E. Bacon, and J. M. Peters, “Programmable Gene Knockdown in Diverse Bacteria Using Mobile-CRISPRi,” Current Protocols in Microbiology, 2020, Vol. 59 (1), e130. doi: 10.1002/cpmc.130.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

